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Endogenousintestinalmicroﬂoraandenvironmentalfactors,suchasdiet,playacentralroleinimmunehomeostasisandreactivity.
In addition, microﬂora and diet both inﬂuence body weight and insulin-resistance, notably through an action on adipose cells.
Moreover, it is known since a long time that any disturbance in metabolism, like obesity, is associated with immune alteration,
for example, inﬂammation. The purpose of this review is to provide an update on how nutrients-derived factors (mostly focusing
on fatty acids and glucose) impact the innate and acquired immune systems, including the gut immune system and its associated
bacterial ﬂora. We will try to show the reader how the highly energy-demanding immune cells use glucose as a main source of
fuel in a way similar to that of insulin-responsive adipose tissue and how Toll-like receptors (TLRs) of the innate immune system,
which are found on immune cells, intestinal cells, and adipocytes, are presently viewed as essential actors in the complex balance
ensuring bodily immune and metabolic health. Understanding more about these links will surely help to study and understand in
a more fundamental way the common observation that eating healthy will keep you and your immune system healthy.
Copyright © 2008 Isabelle Wolowczuk et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. TOLL-LIKE RECEPTORS AT THE CROSS-ROAD
BETWEEN IMMUNITY AND METABOLISM
The relationship between nutrition and the immune system
has been a topic of study for much of the 20th century. Con-
sequently, the dramatic increases in the understanding of the
organizationoftheimmunesystemandthefactorsthatregu-
late immune function have supported the close concordance
between host nutritional status and immunity.
1.1. Theimmunesystem:theconceptof
“immunerecognition”
Classically, the mammalian immune system consists of
innate and adaptive mechanisms that protect the host
from environmental pathogens. Innate mechanisms func-
tion independently of previous exposure of the host to
the infectious agent, and include mechanical barriers (e.g.,
skin, mucosal epithelium) and cellular components (e.g.,
mostly macrophages and neutrophils). In contrast to the in-
nate immune system, the cellular (e.g., mostly B- and T-
lymphocytes) and molecular basis of adaptive mechanisms
relies on speciﬁc recognition of the invading agent and, like
innate immunity, leads to the generation of immunological
memory, that is, a property whereby an individual, after con-
tacting an antigen for the ﬁrst time, acquired the capacity
to respond better and quicker upon reexposure to the same
antigen.
Both innate and adaptive mechanisms are based on
the general process of “immune recognition,” which has
always been one of the main points of interest in im-
munology. For innate immunity, recognition is based on
the use of germline-encoded receptors, whereas in adap-
tive immunity it involves somatically generated receptors.
Nevertheless, beyond the diﬀerent genetic nature of the re-
ceptors, the distinction between the two types of immune
recognition—although useful in many ways—may obscure2 Clinical and Developmental Immunology
the heterogeneity of receptors and mechanisms of innate im-
mune recognition.
The more recent advances in the ﬁeld strongly suggest
that the separation between innate and adaptive immunity
may be too simplistic, notably at the cellular level. The actual
concept is based on the existence of a continuum of immune
cell populations highlighting the complex interplay between
diverse cells of both innate and adaptive immune responses.
Belowwewillreviewthemostrecentﬁndingsintheﬁeld,
focusing on the TLRs, which are now known to be the key
regulators of both innate and adaptive immunities. Interest-
ingly,wewillindicatehowthesameTLRshavebeenreported
to participate in metabolic integrity of a healthy individual.
1.2. Toll-likereceptors:frominnateto
adaptiveimmunity
As mentioned above, the innate immune system allows a
ﬁrst-line protection to a broad variety of environmental
pathogens independent of previous exposure to the infec-
tious agent. It responds quickly and without memory capa-
bility, as opposed to adaptive immunity.
The innate immune system, through germline-encoded
receptors, recognizes a limited set of conserved compo-
nents of bacteria, parasites, fungi, or viruses, known as
“pathogen-associated molecular patterns” (PAMPs). These
receptors have therefore been called “pattern recognition
receptors” (PRRs). Host cells express various PRRs that
sense diverse PAMPs, ranging from lipids, lipopolysaccha-
rides, lipoproteins, proteins, and nucleic acids. Recognition
of these PAMPs by PRRs results in the activation of intra-
cellular signaling pathways that culminate in the production
of inﬂammatory cytokines, chemokines, or interferons, thus
alerting the organism to the presence of infection [1].
Amongst others, PRRs include the members of the TLRs
family [2], the nucleotide-binding oligomerization domain
receptors (NOD-like receptors, NLRs) [3] and the retinoic
acid-inducible gene-like helicases (RIG-like helicases, RLHs)
[4]. Since their discovery, less than a decade ago, both TLRs
and NLRs have been shown to be crucial in host protection
against microbial infections but also in homeostasis of the
colonizing microﬂora, as described in Section 1.3.
To date, the best characterized PRRs are the TLRs, a fam-
ily of transmembrane receptors, the ligand-binding leucin-
rich repeat domains of which interact with extracellular or
membrane-enclosed (i.e., endosomal) intracellular PAMPs.
Remarkably, TLRs are evolutionary conserved from plants to
vertebrates.Inmammals,13TLRshavebeenidentiﬁedsofar:
10human(TLR1-10)and12murine(TLR1-9and11–13)re-
ceptors, of which some are homologous [5]. They are classi-
ﬁedinto severalgroups basedon the type of PAMPsthey rec-
ognize (considering the TLRs that we will mostly describe in
this review: TLR2 senses bacterial lipoproteins, TLR4 senses
lipopolysaccharide(LPS)).Twomajorsignalingpathwaysare
involved after TLR-ligand recognition. One pathway requires
the adaptor molecule MyD88 while the other requires the
adaptor Toll/IL-1 receptor (TIR)-domain-containing adap-
tor inducing IFN-β (TRIF), both involving translocation of
NFκB into the nucleus [6].
TLRs are broadly expressed in cells of the innate immune
system such as macrophages, epithelial and endothelial cells,
and in organ parenchyma cells, and have therefore speciﬁc
roles in local innate immune defense [7].
Besides this ﬁrst line of host defense towards micro-
bial infections, the adaptive immune system is elicited later
(around 4 to 7 days post-infection) and includes a speciﬁc
and long-lasting immunity that is based on the rearrange-
ment and the clonal expansion of a vast and random reper-
toire of antigen-speciﬁc receptors expressed on B- and T-
lymphocytes (resp., B cell receptor: BCR and T cell receptor:
TCR).
Interestingly, various TLRs are also expressed in cells of
the adaptive immune system including B cells, mast cells, T
cells, and dendritic cells (DCs), which are the key cells ini-
tiating the adaptive immune response. Indeed, TLR signals
induce DC diﬀerentiation and cytokine production, conse-
quently inﬂuencing the outcome of their interactions with T
cells and therefore the subsequent development of the adap-
tive immune responses [8]. Recent in vitro studies demon-
strate that TLR signals also trigger striking reorganization
of the vacuolar compartments and aﬀe c tM H Cc l a s sI Ia n d
membrane traﬃcking of DCs [9]. In addition, certain TLRs
are also expressed in T lymphocytes, and their respective
ligands can directly modulate T cell function. For example,
TLR2, TLR3, TLR5, and TLR9 were shown to act as costimu-
latoryreceptorswhichenhanceproliferationand/orcytokine
production of TCR-stimulated T-lymphocytes [10]. Further-
more, speciﬁc subsets of T cells might selectively express dif-
ferent TLRs [11, 12]. Indeed, TLR4 is expressed by na¨ ıve
CD4+ T cells in mice and in a CD25+ subset corresponding
to regulatory T cells in humans. In addition, TLR2, TLR5,
and TLR8 modulate the suppressive activity of naturally oc-
curring CD25+CD4+ regulatory T cells. In B-lymphocytes,
TLR signaling pathways also contribute to their activation
and diﬀerentiation, mostly through the expression of TLR7
and TLR9 [13, 14].
Therefore, in addition to cells of the innate immune sys-
tem, cells of the adaptive immune response, notably T- or B-
lymphocytesanddendriticcells,expresscertainTLRsandre-
spond directly to corresponding ligands in concert with TCR
or BCR signals of lymphocytes. Thus in addition to their
well-described role in innate immunity, TLRs are also crucial
in shaping the adaptive immune response from its initiation
to the development of immunological memory.
1.3. Toll-likereceptors:roleinmucosalimmunity
Human and other mammalian mucosal surfaces are colo-
nized by a vast, complex, and dynamic bacterial community.
In human, the number of microbes associated with mucosal
surfaces exceeds by 10 times the total number of body cells.
This microbiota is constituted of more than 400 species, the
collective genome of which being estimated to contain 100
times more genes than the human genome [15]. In the intes-
tine, the microﬂora is in permanent contact and reciprocal
interaction with the host cells and with nutrients, compos-
ing an extremely complex and highly regulated ecosystem.Isabelle Wolowczuk et al. 3
Theintestinalﬂoraplaysanimportantroleinnormalgut
function and maintenance of the host’s health. It is estab-
lished almost immediately after birth and is now considered
to be essential in priming the immune system during on-
togeny and in the development and maturation of both mu-
cosal and systemic immune systems [16, 17]. Diﬀerent fac-
tors contribute to the protective function of gut microﬂora
such as (1) maintaining a physical barrier against coloniza-
tion or invasion by pathogens, (2) facilitating nutrient di-
gestion and assimilation, and (3) providing immunological
surveillance signals at the gut mucosa-lumen interface.
The microbiota is composed of potentially pathogenic
bacteriabesidesnumeroushealth-promotingnonpathogenic
microorganisms. To control the resident colonizing mi-
croﬂora, as well as to ﬁght pathogens, the human body has
developed a variety of host defense mechanisms that in most
cases eﬀectively prevent the development of invasive micro-
bial diseases [cf. Sections 1.1 and 1.2]. Commensals have
been part of human microecology for millennia, however
these “good bugs” are now less frequent or even absent in
the microbial environment of our industrialized countries.
Therefore,alinkbetweentheincreasingincidenceofallergies
(Th2-driven pathologies) and the modern hygienic lifestyle
has been suggested. This hypothesis, better known as “the
hygiene hypothesis,” puts forward a dysregulation in the T
helper (Th)1/Th2 balance but does not explain the increased
incidence of several other immunological disorders such as
inﬂammatory bowel diseases, multiple sclerosis, type 1 di-
abetes, and obesity, which are all primarily driven by Th1
cells [18, 19]. Recent ﬁndings have suggested that induc-
tion of regulatory T cells by certain microorganisms can pre-
vent or alleviate such diseases [20]. Moreover, defects in such
immunoregulatory processes, such as tolerance against the
commensal microﬂora, have been shown to be associated to
the pathogenesis of inﬂammatory bowel disease (IBD) [21].
Most interestingly, it was recently suggested that disrup-
tion of the mucosal barrier leads to the exposure of a multi-
tude of commensal-derived TLR ligands that could interact
with TLRs-expressing immune cells, consequently leading to
potent inﬂammatory responses [22].
Paradoxically, nonpathogenic bacteria are thought to
contribute to immune homeostasis, not only by maintain-
ing microbial equilibrium but also by regulating the gut im-
mune system. Indeed, commensal bacteria may directly in-
ﬂuence the intestinal epithelium to limit immune activa-
tion. As mentioned before (cf. Section 1.1), commensal and
harmful bacteria express conserved molecular features of
microbes (i.e., PAMPs) necessary for stimulation of innate
and/or adaptive immunity. Nevertheless, despite the fact that
commensal bacteria per se are able to trigger PRRs, they do
not induce inﬂammatory responses. To explain this apparent
contradiction,ithasbeensuggestedthat,whereaspathogenic
bacteria can pass through the epithelial barrier and activate
the TLR-dependent inﬂammatory cascade (notably by in-
ducing NFκB translocation), commensals would be seques-
trated at the epithelial cell surface [23, 24].
Recent ﬁndings also reported a novel function of TLR
signaling in intestinal homeostasis. Using knock-out mice,
Rakoﬀ-Nahoum et al. [25] demonstrated that the recogni-
tion of the commensal microﬂora by TLRs is required to
dampen physiological inﬂammation present at the steady
state, explaining why any disequilibrium in this signal-
ing pathway will lead to inﬂammatory bowel diseases. Re-
cent studies in mice also showed that in vivo ablation of
NFκB activation in colonic epithelium caused severe chronic
intestinal inﬂammation [26], demonstrating that NFκBs i g -
naling is a critical regulator of epithelial integrity and in-
testinalimmunehomeostasis.Moreover,severalreportsindi-
cated that commensals are able to dampen intestinal inﬂam-
mationbyinhibitingtheNFκBsignalingpathway.Neishetal.
[27] ﬁrst showed that avirulent Salmonella abrogates the in-
ﬂammatory cascade by inhibiting ubiquitination and degra-
dation of IκB, thus blocking the transactivation of NFκB-
mediated genes. More recently, Kelly et al. [28] identiﬁed an
interesting mechanism by which commensal ﬂora may reg-
ulate host inﬂammatory responses and maintain immune
homeostasis, more particularly by promoting nuclear ex-
port of NFκB subunit relA, through a PPAR-γ-dependent
pathway. Another possible mechanism to inhibit inﬂamma-
tory responses at mucosal sites is the generation of toler-
ance to a subsequent stimulation from bacterial products.
Otte et al. [29] reported that repeated contact with bacte-
rial components (e.g., lipopolysaccharides) down-regulated
epithelial TLR expression, and inhibited intracellular signal-
ing through TLRs by up-regulating Tollip, an inhibitor of
TLR-mediated cell activation. These data collectively sug-
gest mechanisms whereby inﬂammatory responses induced
by commensal bacteria are inhibited to create and maintain
a state of “immunological silence” at the intestinal mucosa.
BesidesTLRs,otherPRRshaverecentlybeenshowntobe
involved in these processes, notably members of the NOD-
like receptor (NLR) family. NLRs can detect bacterial com-
ponents such as muramyldipeptide (MDP) (recognized by
NOD-2) and muropeptides containing mesodiaminopimelic
acid (recognized by NOD-1).
It is known that NOD signaling involves the activation of
NFκB pathway, but surprisingly, mutations in the CARD15
gene, aﬀecting NOD-2 function, increase the susceptibility
to Crohn’s disease [30]. Recent papers reported that NOD-2-
deﬁcient antigen presenting cells (APCs) showed increased
NFκB activation and IL-12 production upon exposure to
peptidoglycan (PGN), a TLR2 ligand that could also give rise
toMDP,andthespeciﬁcligandofNOD-2.Inaddition,itwas
shown that MDP could down-regulate the IL-12 response of
normal APCs to PGN [31]. Using transgenic mice, the same
group showed that mice overexpressing NOD-2 exhibited
greatly decreased IL-12 responses to systemic administration
of PGN but not to LPS and are partially resistant to colitis in-
duction. These results brought new evidence that defects in
the NOD-2 signaling will contribute to inﬂammatory bowel
diseases by leading to excessive TLR2-dependent inﬂamma-
tory responses [32]. The authors hypothesized that mucosal
APCs are normally exposed to PGN derived from commen-
sal bacteria leading in normal individuals to innate immune
responses.Thisresponsewouldbereasonablyweak,owingto
NOD-2 modulation and also through the induction of reg-
ulatory responses. In case of NOD-2 signaling defects, the4 Clinical and Developmental Immunology
TLR2-dependent inﬂammatory response could not be con-
trolled, therefore leading to mucosal injury.
It is now well accepted that homeostasis versus chronic
intestinal inﬂammation is determined by the presence or
absence of appropriate control mechanisms that could be
linked to a balance between protective (“good”) and aggres-
sive (“bad”) luminal bacteria. Indeed, recent ﬁndings re-
ported notable inﬂuence of the microbiota composition on
the incidence of emerging pathologies such as inﬂammatory
bowel diseases (IBD) and obesity. Metagenomic analysis in-
dicates that the microﬂora of IBD patients is unstable and
presents a reduced complexity of the bacterial phylum Fir-
micutes. Conversely, a shift in the ratio of Bacteroidetes to
Firmicutes has been observed in obese patients as well as in
leptin-deﬁcient obese mice (ob/ob)[ 33, 34]. Thus, the out-
come of severe and critical illnesses seems to be strongly re-
lated to environmental factors and their interaction with the
innate immune system. As we described above, cooperative
as well as competitive interactions may occur between diﬀer-
ent microbial ligands via TLRs and NODs or via other com-
ponents of the innate immune system, leading to either pro-
tective or deleterious responses.
1.4. Toll-likereceptors:roleinmetabolism
Interestingly, in addition to playing a crucial role in immu-
nity, some of the mammalian TLRs have been described to
regulate bodily energy metabolism, mostly through acting
on adipose tissue. This has recently opened new avenues
of research on the role of TLRs in pathologies related to
metabolism,suchasobesity,insulinresistance,oratheroscle-
rosis.
1.4.1. TLRssenselipidsandlipidsactonTLRs
As previously discussed (Section 1.2), TLRs can recognize
several types of components, among which lipids. It has
been shown that some agonists of TLRs contain a lipid moi-
ety comprising saturated fatty acids in acetylated form and
whichisessentialfortheagonisticactivity.Thisisthecasefor
the lipid A moiety that supports most of the biological activ-
ity of LPS, the ligand of TLR4 [35], or for the lipopeptides
which activate TLR2. Interestingly, if the acetylated saturated
fatty acids of these TLR agonists are deacetylated or replaced
by unsaturated fatty acids, the agonists lose their activity or
act as antagonists [36, 37].
Starting from these observations, Lee and collabora-
tors postulated in 2001 that fatty acids could possibly di-
rectly modulate TLR activation and expression of target gene
products [38]. These authors reported that saturated fatty
acids were able to induce the activation of TLR2 and TLR4,
whereas unsaturated fatty acids inhibited TLR-mediated sig-
naling pathways and gene expression (reviewed in [39]).
Both activation of MyD88-dependent and TRIF-dependent
TLR signaling pathways were achieved by saturated fatty
acids. Inversely, unsaturated fatty acids suppressed NFκB
activation induced by LPS, the TLR4 agonist. Importantly,
this inhibitory eﬀect of PUFAs on LPS-induced inﬂamma-
tion was veriﬁed with blood peripheral monocytes harvested
from people given a diet containing ﬁsh oil, a major source
of n-3 PUFAs. Finally, this dichotomy of eﬀects depending
on fatty acid type was not only observed with macrophages
but also with dendritic cells, implying that lipids can aﬀect
cells of both the innate and the adaptive immune systems.
Through TLR4 activation, saturated fatty acids could up-
regulate the in vitro expression of costimulatory molecules
(e.g., CD40, CD80, and CD86), MHC class II and cytokines
(e.g., interleukin (IL)-6 and -12) on DCs, increasing there-
fore their capacity to activate T cells. Again, this activation
was inhibited by adding unsaturated fatty acids, or when
using a dominant negative mutant of TLR4. However, op-
posite eﬀects were obtained in vivo and dyslipidemia re-
sulting from high-fat feeding was hypothesized to impair
TLR-induced activation of mouse dendritic cells [40]. In-
deed, a defect in CD8α− myeloid dendritic cells was ob-
served in mice after high-fat diet, leading to impaired Th1
and enhanced Th2 responses, and to increased susceptibil-
ity to pathogens. Recently, Shi et al. postulated and demon-
strated that TLR activation achieved by fatty acids from
diet origin led to proinﬂammatory cytokine production, and
thereby promoted insulin-resistance [41]. Nutritional satu-
rated fatty acids potently stimulated IL-6 or tumour necrosis
factor (TNF)-α mRNA expression in macrophage-like cells,
whereas food-derived polyunsaturated fatty acids had no ef-
fect alone but inhibited saturated fatty acid-induced TNF-α
mRNA expression. Additionally, macrophages isolated from
TLR4-deﬁcient mice showed blunted cytokine expression in
response to saturated fatty acid treatment.
Compared to TLR4, the direct interaction of TLR2 with
lipids is less documented, but the existence of a link between
lipids and TLR2-signaling has been suggested. Activation of
TLR2 is mainly involved in promoting vascular inﬂamma-
tion and the development of the atherosclerotic plaque. In-
activation of TLR2 expression by knockout technology was
shown to protect atherosclerosis-susceptible mice from the
development of disease [42]. Indeed, TLR2 forms complexes
in lipid rafts with CD36, a membrane receptor which binds
fatty acids and facilitates their transfer into the cells and
which is involved in atherosclerosis progression [43]. Amaz-
ingly,CD36wasdescribedasfacilitatingTLR2signaling[44].
Thus the interaction of lipids with diﬀerent partners of the
TLRs family could take diverse aspects other than a direct in-
teraction.
In conclusion, beside its primary function in alerting the
immune system to the presence of pathogenic microorgan-
isms, TLRs could also sense pathological levels of lipids. In
this context, it is interesting to notice that LPS presented
an anorexigenic eﬀect that was blunted in TLR4-deﬁcient
mice [45], and that TLR4-deﬁciency could eventually lead
to change in eating behaviour, either increasing or decreas-
ing food intake [41, 46, 47] (cf. Section 1.4.3). Therefore, it
is tempting to speculate that detection of abnormal levels of
dietary lipids by TLRs could participate to the sensing of the
energy state of the body and to the subsequent control of
food intake. However, more studies are still needed to clar-
ify the controversial results concerning food intake status in
TLR4-deﬁcient mice before concluding on a potent role of
TLRs in the regulation of food intake. Regarding this, oneIsabelle Wolowczuk et al. 5
should particularly consider the involvement of LPS in these
diﬀerent models.
TLRs are widely distributed in the body notably in the
brain where these receptors are expressed by glial cells [48,
49] and by endothelial cells forming the vessels that irri-
gate the brain [50]. It has recently been reported that TLR2
and TLR4 are expressed by cortical neurons [51] and inter-
estingly, these neuronal TLRs appeared to be insensitive to
bacterial motifs despite being reactive to endogenous prod-
ucts such as the heat shock protein 70. To our knowledge,
the precise analysis of TLR activation in the hypothalamus
(the brain region mostly dedicated to food intake and body
weight control) has not yet been achieved. This would be of
fundamental importance to possibly envisage the participa-
tion of TLRs in the central control of energy homeostasis.
1.4.2. TLRsareexpressedonadiposecells
Insights obtained over the last years have shown adipose tis-
sue to be a true immunocompetent organ and adipocytes as
intricate components of the innate immune system. Indeed,
adipocytes produce numerous inﬂammatory molecules such
as IL-6 or TNF-α [52, 53]. In addition, leptin, the cham-
pion of adipocyte-speciﬁc factor, has been shown to play
an essential role in both innate and adaptive immune re-
sponses [54]. Besides, adipocytes and macrophages (the pro-
totypes of cells involved in innate immunity) were recently
described to originate from a common ancestral progeni-
tor and to share several features [55–57]. Macrophages ex-
p r e s ss o m ea d i p o c y t e - s p e c i ﬁ cg e n ep r o d u c t ss u c ha sa p 2 ,
while adipocytes secrete macrophage-speciﬁc gene products
such as IL-6 or TNF-α. This common gene expression re-
sults in some analogous functional activities, such as lipid
accumulation by macrophages in atherosclerotic lesions or
phagocyticcapacitiesexhibitedbyadipocytestowardscertain
pathogens, thus revealing an apparent coordinated activity
between these two cell-types during the course of an innate
immune response.
An additional similarity between adipocytes and macro-
phages was further revealed with the reporting of the ex-
pression of TLR4 (the TLR mostly known to sense LPS)
by the murine preadipose cell line 3T3-L1 [58]. Interest-
ingly, LPS-treated adipose cells secrete increased amounts
of TNF-α, and subsequently express higher levels of TLR2.
Recently, the presence of functional TLR2 and TLR4 was
reported on human adipocytes isolated from subcutaneous
fat tissue [59], and several TLRs (TLR1 to 9) were found
on adipocytes derived from murine adipose tissue [60, 61].
Activation of adipocytes via TLRs (mostly TLR4) results
in synthesis of proinﬂammatory factors such as TNF-α or
IL-6, and of chemokines such as CCL2, CCL5, or CCL11
[58, 59, 62]. Conversely, adipocyte-speciﬁc knockdown of
TLR4 (e.g., shRNAi for TLR4 in 3T3-L1 cells; or adipocytes
from TLR4-deﬁcient mouse) prevented cytokine expression
induced either by LPS or by saturated fatty acids. Finally,
adipocytes isolated from diet-induced obese mice or geneti-
cally obese animals (ob/ob or db/db) exhibited increased TLR
expression [41, 61, 63], together with higher cytokine pro-
d u c t i o nu p o ns t i m u l a t i o n[ 61].
1.4.3. TLRs,fattyacidsandthemetabolicsyndrome
The observations summed up above may indicate that the
triad “adipocyte-macrophage-TLR4” might be involved in
the inﬂammatory process occurring in obesity. Indeed in the
obese state, a marked inﬁltration of macrophages is observed
within the adipose tissue. Suganami et al. showed that lipol-
ysis and proinﬂammatory cytokine production were reduced
when adipocytes isolated from obese mice were cocultured
with TLR4-deﬁcient macrophages, compared to wild-type
macrophages [64]. Thus the duo “saturated fatty acids plus
TLR4” might be responsible for the ampliﬁcation of inﬂam-
mation occurring in obesity. In this vicious circle, increased
amount of saturated fatty acids (provided either by high-fat
feedingoradipocytelipolysis)couldserveasnaturallyoccur-
ring ligands for TLRs (mainly TLR4), resulting in the activa-
tion of both adipocytes and macrophages to produce proin-
ﬂammatory products, ultimately leading to the development
of the metabolic syndrome.
This seems to be the case, since mice genetically deﬁcient
i nT L R 4o ri nC D 1 4( ac o r e c e p t o rf o rT L R 4 )w e r er e p o r t e d
to be of “ideal body type” when fed on regular chow, having
increased bone mineral content, density, and size, as well as
decreasedbodyfat[65].Moreover,thesemicedonotbecome
obese with age, unlike many strains of laboratory wild-type
mice. This “perfect” phenotype of low adiposity and strong
bones,withnormalactivityandfertilitywasbaptizedas“The
Adonis phenotype” and the concept is currently further ex-
plored for its potential in the treatment of obesity.
However, this approach has to be considered with cau-
tion since contradictory results have been obtained with
high-fat-fed TLR4-deﬁcient mice. Indeed, while some re-
ports described no eﬀect on body weight [46, 64, 66], other
authors described an increased body weight [41] or, in con-
trast, a protection against diet-induced obesity [47]. Simi-
larly,adiposityandfoodintakewereeitherreportedtobeun-
changed, increased, or decreased in TLR4-deﬁcient animals
[41, 46, 47, 64]. Even though these studies were conducted
on mice with diﬀerent genetic backgrounds or obtained with
diﬀerent TLR4-mutating strategies and using diﬀerent feed-
ingprotocols(e.g.,dietcompositionandtiming),anddespite
thediscrepanciesobtainedonbodyweightandadipositylev-
els, they all revealed a marked improvement in insulin sensi-
tivity in the TLR4-deﬁcient mouse as compared to the WT
animals. Therefore TLR4, being expressed in most tissues of
the body—including the insulin-sensitive ones such as adi-
pose tissue (cf. Section 1.4.2), muscle, and liver [47]—and
duetoitsactivationbylipopolysaccharideandsaturatedfatty
acids, which are both inducers of insulin-resistance, appears
to be an essential mediator of bodily insulin-resistance. In-
terestingly, it has been suggested that both TLR2 and TLR4
might be involved in hepatic lipid traﬃcking and storage
[67], yet their precise role in fat accumulation in the liver still
needs to be determined.
Along the same lines another PRR, known as receptor of
advanced glycation end products (RAGE), has recently been
put in the spotlight. The interaction between RAGE and its
ligands, advanced glycation end products (AGEs) such as
lipids and nucleic acids resulting from oxidative stress and6 Clinical and Developmental Immunology
hyperglycemia [68], activates NFκB, which leads to tran-
scription of proinﬂammatory factors [69]. Even if their rele-
vance for obesity is still unclear, AGEs were shown to accu-
mulate in pathological conditions such as diabetes or under
particular life-style habits such as unhealthy diet consump-
tion [70]. Furthermore, RAGE and its ligands have been
implicated in multiple chronic inﬂammatory diseases such
as atherosclerosis and diabetes [71]. Interestingly, alike the
canonical Toll receptors, RAGE is expressed in macrophages
[72], and several experimental evidences strongly support a
role for RAGE in innate immune responses [73].
2. ENERGETIC DEMANDS OF THE IMMUNE SYSTEM:
A SPECIAL TRIBUTE TO DIETARY LIPIDS AND
TO GLUCOSE
Despite the apparent independence between the ﬁelds of im-
munology and nutrition, myriad observations, some quite
old and some quite new, clearly show that the immune sys-
tem cannot function under circumstances of malnutrition,
whether over- or undernutrition [74].
Indeed, lipids consumed in the diet (e.g., fatty acids,
cholesterol, or fat-soluble vitamins), glucose, or oligoele-
ments (e.g., zinc, copper, and iron) deeply aﬀect the immune
system.Revealingthisstrongdependenceoftheimmunesys-
tem upon nutrition, is the fact that nutritional deﬁciencies
are presently considered to be the most common cause of
secondary immunodeﬁciencies in humans.
2.1. Historicalbackgrounds:importanceof
zincandlipids
Historically, the model of zinc-deﬁciency states as the best
characterized nutritional-immunological paradigm. Zinc-
deﬁciency was shown to impact on B-cell lymphopoiesis and
toinducepotentatrophyofthethymus,subsequentlyleading
toadeclineinthenumberofperipheralT-lymphocytes,both
in a murine model of zinc deﬁciency and in zinc-deﬁcient
humans [75–77]. In fact, this anatomical link between nu-
trition and immunology reﬂected by the description of the
thymus as the “barometer of nutrition” was recognized long
beforethethymuswasfoundtobeofkeyimmunologicalim-
portance. The crucial role of zinc or other oligoelements, in
the immune system, has been extensively described in ex-
cellent reviews which we invited the readers to go through
[78, 79].
Considering the inﬂuence of dietary lipids on immune
function, it is rather surprising that this relation was only se-
riously investigated during the past two decades. It is clear
from whole-animal studies that obesity and consumption of
high fat-diets, particularly saturated fat, depress both innate
and adaptive immunocompetences by aﬀecting the activity
of immune cells such as macrophages, dendritic cells, or T
lymphocytes,therebyenhancingtheriskforseriousinfection
and cancers.
The relationship between lipids and immune response
is complex, multifactorial, and still poorly understood. Be-
side individual susceptibility, linked to genetic factors, the
deleterious eﬀect of fat depends largely on the quantity and
the quality of the lipid species consumed. Classically, satu-
rated fatty acids are presented as “bad lipids” by increasing
total cholesterol and as being associated with inﬂammation
andincreasedcardiovascularevents.Incontrast,unsaturated
fats and particularly omega-3 fatty acids are considered to be
“goodlipids”bydecreasingcholesterolandbypreventingad-
verse symptoms of metabolic syndrome such as insulin resis-
tance and inﬂammation. Exhaustive reviews treating the ef-
fects of fat ingestion on molecular and cellular aspects of im-
munity have been published [80–82], and will not be further
developed here. Therefore, we restrict ourselves to present
some selected aspects of these interactions, before discussing
some examples of the consequences of high-fat feeding on
immune reactivity in the light of some of the results we re-
cently obtained.
Besides modulation of immune responses via interac-
tions with Toll-like receptors at the surface of immune cells
(see Section 1.4), lipids appear essential in the performance
of immune cells both as energy suppliers and as constituents
of the membrane architecture. The lipids involved originate
either from the white adipose tissue or directly from nutri-
tion.
In case of a foreign attack, energy needs to be delivered
very rapidly, allowing an immediate reaction of the body. An
essential contribution of the adipose tissue is then to sup-
ply immune cells with fatty acids, which will serve as fuel, as
wellaslipid-basedmessengermolecules.Indeed,arachidonic
acid and docohexanoic acid, two lipid-derived messenger
molecules originating from polyunsaturated fatty acids (PU-
FAs), are key factors in innate immune processes, since they
are the precursors for prostaglandins and leukotrienes, both
largely involved in inﬂammation [83]. This may also explain
why lymph nodes are always embedded within fat depots,
thus emancipating the immune system from competition
with any other tissue [84]. In vivo, following a local immune
activation, spontaneous lipolysis is observed speciﬁcally in
theadipocytessurroundinglymphnodes,implyingtheactive
participation of these adipose cells in local and transient im-
mune responses [85]. This close interaction between adipose
and lymphoid tissues was veriﬁed in some chronic patholo-
gies where selective expansion of perinodal adipose depots
is evidenced, while other depots are depleted [86]. This is
the case of Crohn’s disease, which aﬀects the alimentary tract
and in which only fat depots associated to mesenteric lym-
p h o i dt i s s u ee x p a n d[ 87, 88]. It was also observed in long-
term treated HIV patients, where change of adipose tissue
distribution (HARS; HIV-associated adipose redistribution
syndrome, [89]) could be due to the prolonged activation of
perinodal adipose tissue, resulting in enlargement of node-
containingdepots,attheexpenseofnodelessdepots[86,90].
Moreover, lipids are major components of cell mem-
branes, and combinational associations of diﬀerent lipid
species will generate microheterogeneity in cell membranes,
leading to the formation of microdomains, termed rafts
[91, 92]. Diﬀerences in lipid raft composition and organi-
zation have been associated with diﬀerences in T cell signal-
ing and in synapse formation between APC and T cells [93–
95]. Furthermore, a diﬀerential implementation of rafts has
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indicating that the regulation of T cell signaling and activa-
tion by lipid diet may be crucial in Th1/Th2 cell orientation
[96]. The lipid-content of the membrane of dendritic cells
and lymphoid cells in nodes containing depots was shown to
correlate well with that of the adjacent adipocytes [97]. Con-
jointly, besides de novo synthesis from carbohydrates, fatty
acids deposited in adipose tissue can originate from dietary
sources. Thus, any diet-induced variation in lipid composi-
tion of fat depots may inﬂuence directly the membrane or-
ganization of immune cells and result in impaired function-
ality. Indeed, it was shown that diet has a marked impact on
the lipid composition of cell membranes, leading to changes
in ﬂuidity and organization [98]. In particular, dietary (n-3)
PUFAsalterTcellmembranemicrodomaincompositionand
may therefore inﬂuence signaling complexes and modulate T
cell activation in vivo [81].
2.2. Roleofglucoseintheimmunesystem:
why,when,andhow?
Aswewilldescribeinthelastsection(cf.Section 3.1),ﬂuctu-
ations in blood glucose occur in inﬂammatory diseases such
as obesity, diabetes, and insulin resistance, in which gut mi-
crobiota might play an active role. We will show now that,
in addition to lipids (cf. Section 2.1), glucose should be con-
sidered the quantitatively most important fuel to fulﬁl the
energy requirement of immune cells, therefore it is likely in-
volved in the immune alterations associated with obesity or
diabetes.
2.2.1. Roleofglucoseintheimmunesystem:why?
Theimmunesystem—bothinnateandadaptive—is essential
to prevent or limit infection but is equally important in the
overallprocessofrepairandrecoveryfromanytypeofinjury.
As described in Section 1.3, the immune system also partic-
ipates in the control of the resident colonizing microﬂora
which is essential to the establishment of an “immunologic
and metabolic health.” To exert this variety of fundamen-
tal regulatory processes—some of which being highly energy
demanding—immune cells from the innate and the adaptive
immune systems utilize numerous extracellular molecules
and signals as fuels [99–102]. The exact nature of the ener-
getic demands and how these are met will diﬀer among im-
munecellsandthenatureoftherequiredresponse;forexam-
ple, whether proliferative/secretory (B- or T-lymphocytes)
or nonproliferative/secretory (macrophages or neutrophils)
will be important. However, any type of response will place
large bioenergetic demands on all immune cells. In addition
to glutamine, ketone bodies, or fatty acids, glucose should
be considered the most quantitatively important fuel for im-
mune cells.
Indeed, early studies using lymphocytes stimulated with
B- or T-speciﬁc mitogens (such as pokeweed mitogen (for B
cells), concanavalin-A, or phytohemagglutinin-A (for T
cells)) revealed the importance of glucose uptake and
catabolism in providing energy for their proliferative,
biosynthetic, and secretory activities [103–107]. Within 1
hourofstimulation,mitogen-inducedlymphocyteactivation
led to an increase in glucose consumption, mostly metab-
olized to lactate, highlighting a rapid enhancement of gly-
colysis following lymphocyte activation. Additionally, other
pathways of glucose utilization were also shown to be in-
duced during lymphocyte stimulation, such as the pentose
phosphate pathway which peaked at 48 hours after stimula-
tion,coincidingwiththemaximalproteinandRNAsynthesis
accompanying lymphocyte blastogenesis [108].
Later, the crucial role of glucose in lymphocyte activation
was also reported to be expandable to cells of the innate im-
mune system like macrophages [109] and neutrophils [110].
Although the capacity for rapid cell division does not apply
to these cell types, which are terminally diﬀerentiated and
have little capacity for cell division, macrophages and neu-
trophils have a large phagocytic capacity (requiring a high
rate of lipid turnover and synthesis) and a large secretory ac-
tivity in which glucose was shown to be most likely involved.
To conclude, generating an eﬃcient and eﬀective im-
mune response involves large increases in cellular prolifer-
ative, biosynthetic, and secretory activities, processes which
all require high energy consumption. As mentioned, adap-
tive as well as innate immune cells must be able to rapidly re-
spondtothepresenceofpathogens,shiftingfromaquiescent
phenotype to a highly active state within hours after stimu-
lation. For that purpose, cells must dramatically alter their
metabolism in order to support these increased synthetic ac-
tivities based on extracellular signals as fuels, amongst which
glucose is the most essential one.
2.2.2. Roleofglucoseintheimmunesystem:when?
Lymphocyte development is tightly controlled, starting from
multipotent medullary progenitors to mature lymphoid cells
in the periphery. For T cell lineages, that were more exten-
sively studied for their glucose metabolism than the B-cell
lineages, a crucial checkpoint in T-lymphocyte development
occurs in the thymus where the Notch and the IL-7 recep-
tor (IL-7R) signaling pathways both maintain cell viability
and promote thymocyte diﬀerentiation [111, 112]. Interest-
ingly, it has been shown that both pathways are important
for glucose metabolism in T cells, notably via Akt/PKB ac-
tivation [113, 114]. Resting T cells will later exit the thy-
mus and enter peripheral circulation as small quiescent cells.
These resting cells consume glucose and other nutrients at a
low rate, suﬃcient to maintain normal housekeeping func-
tions. Even to insure this basal metabolic rate, T cells re-
quire extracellular signals from, for example, cytokines as
wellaslow-levelstimulationthroughtheTCR.Intheabsence
of such signals, T cells will reduce their capacity to import
glucose to levels below those necessary to maintain cellular
homeostasis [107, 115, 116]. Thus, the metabolism of rest-
ing lymphocytes is limited by the availability of trophic sig-
nals rather than the availability of nutrients, such as glucose
[117]. Once T cells are activated by mitogens or antigens,
the energy-demanding processes are activated as described
in Section 2.2.1. In order to approximately double their rest-
ing size and enter a program of rapid proliferation while
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activated T cells will strikingly increase their glucose con-
sumption, a demand mostly met through glycolysis [107].
Interestingly, it was recently reported that increased ex-
tracellular concentrations of glucose can protect neutrophils
from apoptotic death and that this protective eﬀect is corre-
lated with the rate of glucose utilization by the cells [118].
Apoptosis is an important feature of neutrophil biology and
prevention of neutrophil death by high glucose concentra-
tionsmightbeseenasbeneﬁcialsincethesecellsarekeycom-
ponents of the innate immune response.
2.2.3. Roleofglucoseintheimmunesystem:how?
Recently, a combination of independent and complementary
studies has provided molecular insights into the regulation
of energy metabolism in immune cells, involving the coor-
dination by signal transduction pathways which act directly
onto the modulation of nutrient uptake and metabolism.
First of all, both the major glucose-transporter (GLUT)
proteins and the insulin receptor (InsR) were shown to be
expressed on immune cells (e.g., monocytes/macrophages,
neutrophils, and B- and T-lymphocytes) [119–121]. Those
receptors are functional since they are responsive to both im-
mune stimulation and insulin [122].
The pattern of GLUT upregulation diﬀers among dif-
ferent types of immune cells. For example, diﬀerentiation
of monocytes to macrophages is associated with an in-
creased expression of GLUT3 and GLUT5, even if their pre-
cise physiological role in macrophages still remains uncer-
tain [123]. Regarding insulin-stimulating glucose transport,
it was shown that physiological doses of insulin led to in-
creased expression of GLUT3 and GLUT4 in monocytes
and B-lymphocytes [124]. In contrast, insulin did not alter
GLUT expression neither in resting T cells nor in neutrophils
[122–124], despite activating the insulin-signaling pathway
[125]. Nevertheless, in vitro mitogen- or LPS- (the ligand for
TLR4) stimulation of immune cells enhanced the expression
ofmembraneGLUTisoforms,mainlyGLUT1,3,and4[122–
124]. Interestingly is to note that the increase in GLUT1 lev-
els upon stimulation was observed with all cell types (e.g.,
monocytes/macrophages and T- and B-lymphocytes), likely
suggesting that GLUT1 might be the isoform which ensures
the provision of glucose for the basic metabolic needs [126].
Important also is the observation that GLUT3 and GLUT4
a n dG L U Ti s o f o r m sw i t hh i g h e ra ﬃnity for glucose were
strongly overexpressed on activated T- and B-cells, therefore
allowing immune cells to compete for glucose when concen-
trations in the surrounding environment are very low. This
is particularly important for lymphocytes, which have low
energy-storage capacity [99] and, as we discussed before, are
highenergydemandersespeciallyinconditionsofactivation.
InadditiontotheincreasedexpressionofGLUTisoforms
upon immune stimulation (i.e., by mitogen or LPS), insulin
withdrawal on immune cells was also reported to modulate
GLUT expression, notably GLUT3 and GLUT4. It has been
proposed that expression of the Insulin receptor is essential
for immune cell division, size, and survival [127] and that
IL-7 would be essential in this process [128].
Secondly, regarding the signaling pathways that modu-
late the glucose uptake and metabolism of immune cells, it
was reported before that treatment of B- or T-cells with in-
hibitors of phosphatidylinositol3-kinase (PI3-K) blunted the
ongoing increase in cell size, and therefore the subsequent
proliferation, probably as a result of a block at a critical early
growth checkpoint [129]. This observation further supports
a key role for glucose metabolism in immune cells.
In T cells, it is known that ligation of the costimulatory
receptor CD28 activates the PI3-K/Akt pathway [130], sim-
ilarly to the binding of insulin to its receptor [131]. There-
fore, CD28 was suggested to be a good candidate for regu-
lating T cell metabolism [116]. Indeed, upon CD28 stimula-
tion, T cells increase GLUT expression, glucose uptake, and
glycolysis and these eﬀects are dependent on PI3-K activity
[116]. Additionally, CTLA-4, an inhibitory receptor with op-
posite eﬀects on T cell activation, can inhibit CD28-induced
increases in glucose metabolism [116].
The precise signaling mechanisms by which growth fac-
tors or cytokines (glucose, insulin, and IL-7 as the most
important ones) prevent atrophy and promote cellular
metabolism in immune cells still remain uncertain. Never-
theless, PI3-K and mammalian target of rapamycin (mTOR)
have been shown to simulate cellular metabolism and are ac-
tivated by a variety of growth stimuli such as glucose, in-
sulin,andIL-7.PI3-Kanditsdownstreamsignalingmolecule
Aktcanpromoteglucoseuptakeandmetabolism[116]while
mTOR is critical in promoting protein-eﬃcient translation
and inhibiting protein degradation [132].
Regarding IL-7, an immune cytokine essential for sur-
vival,cellsize,andTcellactivation,itwasshowntomaintain
glucose metabolism in vitro. Indeed, the addition of IL-7 to
T cell cultures was found to be suﬃcient to maintain glucose
metabolism to approximately normal levels. In addition, like
for insulin/glucose, the trophic eﬀect of IL-7 requires PI3-K
a n dm T O Ra c t i v i t i e s[ 128].
In conclusion, when considering the signaling pathways
involved in glucose metabolism in immune cells, it is gen-
erally accepted that glucose uptake and metabolism are pro-
moted by PI3-K and its downstream signaling molecule Akt
(both in T- and B-lymphocytes). mTOR appears to be more
criticalinfavoringeﬃcientproteintranslationandinhibiting
protein degradation. Interestingly, the crucial role of IL-7 on
T-lymphocyte homeostasis (in mice and human)—known
for a long time—was demonstrated to depend upon these
metabolic pathways since IL-7, alike insulin, promotes T cell
survivalandsize inaPI3-K/Akt andmTOR-dependentman-
ner.
3. SELECTEDEXAMPLESOFTHEIMMUNEREACTIVITY
OF METABOLICALLY ALTERED ORGANISMS
Afterhavingdescribedtheintricaterelationsbetweentheim-
munesystem,selectednutrientssuchasglucoseorlipids,and
theendogenousmicroﬂora,wewillillustratebelowhowmal-
nutrition (mostly overnutrition) can aﬀect immunocompe-
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3.1. Obesity,diabetes,andimmunedysfunction
Theincidenceofobesityandassociatedcomorbidities—such
as type 2 diabetes, insulin resistance, and cardiovascular
diseases—isreachingworldwideepidemicproportions[133–
135]. This pathology is the result of an imbalance between
caloric intake and energy expenditure, resulting in excess en-
ergy storage, mostly due to genetic and environmental fac-
tors. Among the environmental factors thought to play an
importantroleinobesity,weshouldcounttheincreasedcon-
sumption of energy-dense and micronutrient-poor foods,
that is, processed food is usually high in starches, added sug-
ars, and added fats [136, 137].
After a meal, fatty acids and glucose enter the blood. As
shown above, both factors greatly inﬂuence immune home-
ostasisandreactivity.Inobesity,thebodyisliterallysoakedin
excessfatandglucose,likelyparticipatingtotheprofoundal-
terations of immune responsiveness—innate and adaptive—
occurring in the obese state.
Indeed, macrophages accumulated proportionally to
adipocyte size and numbers within the white adipose tissue
of obese mice. In addition, macrophages from this “obese
adipose tissue” displayed impaired functionality with a re-
duced phagocytic capacity and a defective oxidative burst
[138, 139]. More generally, several independent epidemio-
logical studies reported that obese individuals have increased
susceptibility to systemic infections. The obese patients are
morepronetodevelopinfectiouscomplicationsaftersurgery
[140], and a positive correlation between body mass index
(i.e., weight in kilograms divided by height in square meters)
and nosocomial diseases has been reported [141]. Moreover,
upto50%ofobesepersonsdevelopcutaneousinfectionsand
display reduced wound healing capabilities [142–145]. In
longitudinal studies, the incidence of lower respiratory tract
infections was signiﬁcantly higher in obese infants than in
nonobese infants [145]. Chandra [146] reported that obese
children, adolescent, and adults exhibited variable impair-
mentofcell-mediatedimmuneresponsesinvivoandinvitro
aswellasareductionofintracellularbacterialkillingbypoly-
morphonuclear (PMN) leukocytes.
This marked impairment of the immune system associ-
ated with human obesity has also been reported in several
animal models. Obese dogs have a decreased capacity to re-
sist salmonella infection and canine distemper virus [147].
In addition, these obese dogs have shortened average sur-
vival time after distemper infection and the incidence of par-
alytic encephalitis was signiﬁcantly increased [148]. In ro-
dents, it was shown that the obese zucker rats have an in-
creased susceptibility to Candida albicans infections [149],
whereas obese leptin-deﬁcient ob/ob and leptin-resistant di-
abetic db/db mice display an impaired response to Liste-
ria monocytogenes [150]. As in human obesity, obese ani-
mals present a delayed wound healing associated with in-
creased polymorphonuclear cell inﬁltration [151]. In addi-
tion, both T- and B-cell-mediated immune responses were
reported to be impaired in obese ob/ob and diabetic db/db
mice [152, 153].
Finally, obesity is also characterized by an imbalance of
the cytokine network, resulting in a low-grade systemic in-
ﬂammatory status described in both obese humans and an-
imals [154]. The inﬂammatory cytokines IL-6, IL-1, and
TNF-α, abnormally elevated in obesity, mostly originate
from the activated macrophages inﬁltrating the white adi-
pose tissue [138, 139, 155].
Thus, obesity is presently viewed as an inﬂammatory dis-
ease, referred to as “obesitis,” aﬀecting both innate and ac-
quired immune systems [156]. We described in Section 1.4.3
how TLR4 might be involved in the inﬂammation occur-
ring in the obese state, and recent studies reported a pro-
tection of high-fat fed mice against insulin resistance and
vascular inﬂammation in TLR4-deﬁcient mice compared to
WT animals [41, 46, 47, 64]. In human, some associations
between TLR4 polymorphism and vascular inﬂammation,
artherosclerosis and clinical diabetes, have also been pub-
lished [157].
Although many research groups have studied the im-
mune system of obese individuals or animals, there is still
scarce information regarding the eﬀects of obesity on den-
driticcells(DCs),despitetheiressentialroleininnateimmu-
nity and in the induction and regulation of antigen-speciﬁc
adaptive responses [158].
Therefore, we recently characterized DCs in the model
of obese leptin-deﬁcient ob/ob mice [159]. Leptin is an
adipocyte-derived cytokine, secreted proportionally to the
amount of fat, originally characterized for its capacity to
ﬁnely regulate body weight [160]. Indeed, the complete con-
genital absence of leptin leads to a syndrome of intense hy-
perphagia and morbid obesity both in humans and rodents,
which can be reverted by administration of the recombi-
nant molecule [161]. Interestingly, subsequent studies fur-
ther demonstrated that leptin intervenes in both innate and
adaptive immunities. Leptin promotes activation of mono-
cytes/macrophages chemotaxis and activation of PMN cells,
development and activation of natural killer (NK) cells, and
regulation of T cell responsiveness [162]. Therefore, due to
these multiple functions of leptin, mice lacking the func-
tional protein (e.g., the ob/ob m i c e )p r e s e n tab r o a dr a n g e
of endocrine and immune alterations.
Among these immune alterations, we demonstrated that
despitedisplayingnormalphenotypicandfunctionalcharac-
teristics,bothhomeostasisandfunctionalityofDCsweredis-
turbed in ob/ob mice. Indeed, DCs from ob/ob mice were less
potent in stimulation of allogenic T cells in vitro, likely due
to the increased secretion of immunosuppressive cytokines.
Moreover, we showed altered in vivo homeostasis of epider-
mal DCs in ob/ob mice, which was not due to a migratory
defect and which could be restored by intradermal adminis-
t r a t i o no fl e p t i n[ 159].
Along those lines, we also reported the impairment of
immune cells as a consequence of high fat diet- (HFD-) in-
d u c e dw e i g h tg a i n( am o r ep h y s i o l o g i c a lm o d e lo fo b e s i t y
than the ob/ob model) in a study using mice transgenic for
a TCR recognizing a peptide derived from ovalbumin [163].
The study showed that T cell reactivity was impaired by ex-
cess of fat feeding, but amazingly the expression of this ef-
f e c tw a sd e p e n d e n to nw h e t h e rTc e l l sa r en a ¨ ıve or antigen-
experienced. Indeed, T cells from HFD-fed na¨ ıve trans-
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stimulated in vitro with mitogen or antigen, implying that
thesecellslikelyparticipateinthelow-gradesystemicinﬂam-
mation observed in overweight and obese patients. Inversely,
antigen-experienced T cells (from ovalbumin-immunized
HFD-fedmice)presentedamarkeddefectinproliferativeca-
pacity, together with a shift towards a typical Th2 cytokine
secretion proﬁle. Dendritic cells apparently played a pivotal
role in the Th polarization and impaired maturation was as-
sociatedwithaTh2immunedeviation[164].Wedidobserve
that DCs were defective in their capacity to present antigens
toTcellsinHFDanimals.ThisTh2-biasedimmuneresponse
could be involved in the high incidence of infection reported
in obese patients, and in hyporesponsiveness to some vacci-
nation trials [140–146].
Altogether, we demonstrated for the ﬁrst time that the
immune deﬁciency observed in leptin-deﬁcient obese mice,
and maybe in other types of obesity, was associated with an
impairment of dendritic-cell function, the key immune cell
that bridges innate and adaptive immunities.
As stated in the introduction to this last section, fat and
glucose controls are linked: obese people develop insulin re-
sistance and then diabetes, conditions in which glucose up-
takeand production areimpaired duetodefectiveinsulin ac-
tion [133–135]. In Section 2 of our review, we showed how
glucose transport and metabolism in immune cells are sensi-
tive to insulin. In addition, we showed that glucose is a major
fuel used by immune cells, therefore any variation in blood
glucose concentration will likely aﬀect immune responsive-
ness. Indeed, it was reported that acute, short-term hyper-
glycemiaaﬀectsallmajorcomponentsofinnateandacquired
immunities, consequently leading to reduced defense against
infection[165]andinitiatingacascadeofpathologicalevents
resulting in the activation of NFκB[ 166].
In diabetes, where insulin action is defective and hyper-
glycemia chronic, immune T cell functionality is impaired
with reduced ability to produce IL-2 [167] and to proliferate
in response to mitogenic or antigenic signals [168]. Further-
more, neutrophils from diabetic patients showed impaired
respiratory-burst activity [169]. Additionally, a pioneering
studybyVandenBergheetal.[170]reportedthatpatientsre-
ceiving intensive insulin therapy had a signiﬁcantly reduced
rateofinfectionsandwerelesslikelytohaveelevatedmarkers
of inﬂammation.
Nevertheless, despite the fact that increased susceptibil-
ity to infections aﬀects the morbidity and mortality of dia-
beticpatients—whichisofcriticalclinicalimportance—little
is known about how diabetes precisely impair immunity. Re-
garding the essential role played by glucose and insulin on
immune cells, variations in their levels which occur in dia-
betesaremostlikelyinvolvedinimmunedisordersassociated
with this trait.
3.2. Inductionofchronicdiseasesby
microbiotadysbiosis
3.2.1. Symbiosisbetweenthehostanditsmicrobiota
As previously described (cf. Section 1.3), there is a perma-
nent dialogue between the gastrointestinal tract and the in-
testinal microﬂora. The intestinal microbiota is a complex
symbiotic ecosystem which has the capacity to (1) digest
luminal component and (2) synthesize useful host nutri-
ents, while (3) stimulating immune defense mechanisms.
This symbiotic relationship between host and bacteria in-
volves microbial fermentation processes. The predominant
end-products of bacterial fermentation in the gut are short
chain fatty acids, such as acetate, propionate, and butyrate.
Acetate is taken up primarily by peripheral tissues and can
also be utilized by adipocytes for lipogenesis [171]. The in-
testinal microﬂora also contributes to aminoacid synthesis.
Indeed, high concentrations of urea are found in the colon of
germ-free rats, indicating the role of bacteria in intestinal ni-
trogen recycling [172]. The intestinal ecosystem also plays a
crucialroleinthemetabolismoflignan,adietaryphytoestro-
gencompoundfromplantorigin,whichcouldbeinvolvedin
colon cancer, atherosclerosis, and diabetes. Moreover, it has
been proposed that the microbiota deconjugates and dehy-
droxylates bile acids [173, 174], metabolizes bilirubin [175],
reduces cholesterol [176], and degrades mucus glycoproteins
produced by the intestinal epithelium’s goblet cell lineage
[177].
As indicated above, the assembly of the gut microﬂora
commences at birth and its composition will undergo dra-
matic changes during postnatal development. When space
and nutrients are not limited, commensals with high divi-
sion rates will predominate. As the population increases and
nutrients are depleted, niches become occupied with more
specialized species [178, 179]. The ability of other commen-
sals to enter these occupied niches will depend on their abil-
ity to utilize the nutrients substrates more eﬃciently and/or
to modify the nutrient reservoir to better suit their own
metabolic needs. Therefore, an equilibrium between micro-
bial nutrient utilization and host nutrient production should
be achieved which is not deleterious for both partners [180].
Diet is clearly a key factor which regulates the sequence
and the nature of colonization. In breast-fed infants, the in-
testinal ﬂora is dominated by biﬁdobacteria, while formula-
fed infants have a more diverse ﬂora [180, 181]. In breast-
fed infants, the microﬂora produces high amounts of ac-
etateandlactaterestrictingthegrowthofpotentialpathogens
such as Escherichia coli and Clostridium perfringens [182].
In comparison, formula-fed infants produce relatively high
amounts of propionate and butyrate. The favored growth
of biﬁdobacteria in breast-fed infants is likely due to the
presence of neutral oligosaccharides with prebiotic eﬀect,
in the breast milk [183]. Similarly, it has been observed
that the addition of prebiotics to infant regimen can stim-
ulate growth of beneﬁcial endogenous bacteria. As an exam-
ple, feeding infants with formula enriched with galacto- and
fructooligosaccharides signiﬁcantly increased the number of
biﬁdobacteria [184, 185].
3.2.2. Alterationofthemicrobiotaandoutcomeof
chronicdiseases
Although the composition of the microbiota varies along the
lengthofthegutandduring thelifeofthehost,it isquitesta-
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Recent metagenomic studies, however, showed that the mi-
crobial balance is altered in some immune disorders. No-
tably, a signiﬁcant reduction in the diversity of the phyla Fir-
micutes has been reported in patients with Crohn’s disease
(CD). While 43 distinct ribotypes of Firmicutes were identi-
ﬁedinhealthymicrobiota,only13ribotypesweredetectedin
CD patients, indicating a serious degree of microbial dysbio-
sis [186]. Moreover, new species have been identiﬁed in IBD
patients, such as unclassiﬁed Porphyromonadaceae species.
The authors suggested that the onset of the inﬂammatory
disease could be due to this altered microbiota. Notably,
loss of butyrate producers observed could upset the dialogue
between host epithelial cells and resident microorganisms,
hence contributing to the development of CD associated in-
jury.
Giventhe worldwide epidemic in obesity, there is a grow-
inginterestconcerningtheinteractionofthemicrobiotawith
the host in obese state. Previous experiments showed that
colonization of the gut of germ-free mice with microbiota
isolatedfromconventionalanimalsledtoadramaticincrease
of 42% in body fat within 10–14 days, despite decreasing
food consumption. Along the same lines, it was later shown
thatcolonizationofgerm-freemicewithanobesemicrobiota
resulted in a signiﬁcant greater increase in total body fat than
colonization with a lean microbiota [187]. Altogether, these
ﬁndings suggested that the microbiota of obese individuals
m a yb em o r ee ﬃcient at extracting nutritional value from a
given diet than the microbiota of lean individuals [188, 189]
and that this trait is transmissible by the microbiota. Fur-
thermore, the comparison of the gut microbiota of leptin-
deﬁcient obese (ob/ob) mice versus lean mice showed that
the relative abundance of the Bacteroidetesin ob/ob mice was
50%-lower, whereas that of the Firmicutes was 50%-higher
[190].
Interestingly, similar results were reported in obese pa-
tients showing a decrease in the relative proportion of Bac-
teroidetes as compared to lean individuals [34]. Additionally,
when obese patients lost weight over a one-year period, the
proportion of Firmicutes became similar to that of lean in-
dividuals. Recently, the same authors showed that microbial
colonization of gnotobiotic mice led to de novo lipogenesis
andenhancementofadiposityassociatedwithincreasedsup-
pression of intestinal Fiaf expression, a circulating lipopro-
tein fasting inhibitor [191].
All these studies suggest that the obese state is associ-
ated with modiﬁcations in microbiota composition and that
changes in microbial fermentation of dietary polyssacharides
will inﬂuence intestinal absorption of monosaccharides and
short-chain fatty acids and consequently their conversion to
more complex lipids in the liver and deposit of lipids in
adipocytes.
3.2.3. Improvementofthebeneﬁcialeffectof
themicroﬂorabyprobioticsupplementation
Individual human health is determined by a complex inter-
play between genes, environment, diet, lifestyle, and symbi-
otic gut microbial activity. Recognition of the interplay be-
tween genes and diet in the development of certain diseases
and for maintenance of optimal metabolism has led to nu-
trigenomic or nutrigenetic approaches. These might allow to
propose personalized or individualized nutrition in order to
prevent, delay, and/or reduce the symptoms of some chronic
diseases [192]. The ultimate goal of nutrigenomics is there-
fore to apply genomics, transcriptomics, proteomics, and
metabolomicstohumannutritioninordertogetabetterun-
derstandingoftherelationshipbetweenhealthandnutrition.
In addition, nutrigenomics will be useful to demonstrate the
impact of bioactive food compounds on health and also the
eﬀect of healthy food on human health, therefore leading to
the development of “functional food” which should keep in-
dividuals healthy according to their own needs.
The human microbiome project [193] aims to uncover
the functional contributions of gut microbiota and to deﬁne
how microbiota contributes to normal physiology and/or
to predisposition to certain diseases. Nutrigenomics showed
that diet can dramatically alter the microbial composition of
gut microbiota. Current research increasingly recognizes the
human gut microbiome as a metabolically versatile biolog-
ical “digester” that plays an essential role in regulating the
host metabolome [194]. Gut microbiota recovers energy and
biologically active molecules from food which would other-
wise be washed out by the intestinal tract without any ben-
eﬁt for the host. Indeed, predictions of microbial commu-
nitymetabolism,basedoncommunitygenecontentanalysis,
indicated that the obesity-associated gut microbiome has an
increased capacity to harvest energy from the diet. Further, it
is now clear that microbiota has profound regulatory eﬀects
outside the gutsuchas regulationoffatstorage,maintenance
of the intestinal barrier function, and modulation of the im-
mune system. Dysbiosis has been reported both in obesity
and chronic inﬂammatory bowel diseases and a deﬁciency in
“ g o o db u g s ”s u c ha sl a c t o b a c i l l ia n db i ﬁ d o b a c t e r i ah a sb e e n
observed in individuals having a western type of lifestyle.
The demonstration of the importance of human gut mi-
crobiota in health restoration and maintenance has kindled
an interest in probiotics, deﬁned as microbial food supple-
ments which beneﬁcially aﬀect the host by improving its in-
testinal microbial balance. It is now well accepted that sup-
plemented probiotic bacteria might have the capacity to im-
prove the functions of both the innate immune system and
the gut physiology. Indeed, regular intake of probiotic bacte-
ria has been shown to maintain the gut immune homeostasis
by altering microbial balance or by interacting with the gut
immune system, explaining their potential eﬀect in gastroin-
testinal diseases. Probiotics have proven beneﬁts in treat-
ment or prevention of certain type of diarrhea [195], inﬂam-
matory bowel diseases [196, 197], some cancers [198], and
food allergy and atopic eczema in children [199]. Although
there is now considerable body of information concerning
the clinical eﬃciency of probiotics, their mechanisms of ac-
tion remain unclear. Their beneﬁcial eﬀects can be exerted
through diﬀerent means, such as production of antimicro-
bial metabolites, competitive exclusion of enteric pathogens,
or neutralization of dietary carcinogens. Their capacity to
modulate the mucosal immune system is regarded as one
of the most obvious beneﬁcial properties. Indeed we, and
others,showedthatprobioticspresentdistinctstrain-speciﬁc12 Clinical and Developmental Immunology
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Figure 1: After a meal, fatty acids and glucose, through intestinal absorption, enter the blood. Both serve as fuels for cells or tissues, glucose
being the most important to fulﬁll the energy requirement of immune cells, and lipids representing major components of cell membranes.
Besides, food-derived fatty acids, as well as intestinal bacteria-derived fatty acids could be sensed by Toll-like receptors (TLRs) which are
expressed on immune cells, adipocytes or intestinal gut, resulting in activation of the immune system. Depending on the intensity, the
time lasting, and the control of these events, it will either favor the development of an eﬃcient immune defense, or lead to a drift towards
metabolic diseases such as obesity.
immunomodulatory capacities in vitro [200] which can be
closely correlated with their in vivo anti-inﬂammatory po-
tential [201]. We also reported the importance of cell wall
components in the pro- versus anti-inﬂammatory properties
of lactobacilli [202]. Interestingly, the anti-inﬂammatory ef-
fects of lactobacilli observed after either oral or systemic ad-
ministration [203] suggest that the protective mechanisms
might involve regulatory cell populations. Recent studies re-
ported that a deﬁned probiotic mixture ameliorates murine
colitis by inducing regulatory T cells [204] and can induce in
vivo peripheral T cell hyporesponsiveness [205], suggesting
a modulation through dendritic cell (DC) function. We re-
cently showed that selected strains indeed are able to induce
tolerogenic dendritic cells that confer protection in a murine
modelofcolitisuponadoptivetransfer.Thiscapacitywasde-
pendant on both TLR2 and NOD2 signalings, conﬁrming a
k e yr o l eo fc e l lw a l ls t r u c t u r e s[ 206].
Regarding obesity, only few studies have addressed the
potential eﬀects of probiotics in the management of this
disease. Since obesity is presently viewed as an inﬂamma-
tory disease, aﬀecting both innate and acquired immune sys-
tems [156], we could speculate that probiotics with poten-
tial anti-inﬂammatory properties could counteract the de-
velopment of complications associated with this pathology.
Recently, Bleau et al. [207] reported that supernatants from
lactobacilli-treated adipocytes decreased the inﬂammatory-
type response of lymphocytes. These eﬀects were correlated
with a reduction of leptin production by lactobacilli-treated
adipocytes. Finally, a selected strain of Lactobacillus rhamno-
sushasbeenreportedtoprotectmicefromdiet-inducedobe-
sity, likely due to the production of conjugated linoleic acid
by the bacteria [208].
From the limited, yet convincing, studies performed so
far, one can predict that nutrigenomics will improve our
knowledge on the function of gut microbiota and allow ther-
apeutic manipulation of the gut ecosystem to become a valid
and realistic future prospect.
4. CONCLUSIVE REMARKS
The rapid rise in the numbers of obese patients, partly due to
alifestylethatpromotesovereatingandinactivity,ispresently
acriticallyimportanthealthissueworldwide.Obesityisasso-
ciated with a number of diseases collectively summarized as
the “metabolic syndrome,” involving insulin resistance, type
2 diabetes, and cardiovascular diseases.Isabelle Wolowczuk et al. 13
Although obesity results from complex and multiple in-
teractions between genetic and environmental factors, nu-
merous studies provide strong corroborative evidences that
overnutrition can promote metabolic diseases.
Like other chronic disorders of metabolic homeosta-
sis, we showed that obesity is also associated with immune
disbalances, involving low but chronic level of inﬂamma-
tion, as well as inﬁltration of adipose tissue with activated
macrophages.
It has been proposed that chronic activation of the innate
immune system could be regarded as a possible risk factor in
the development of obesity and its associated inﬂammation.
Indeed, signaling receptors of the innate immune system
(suchasTLRs)inducesignaltransductionpathwaysthatlead
to the activation of transcription factors which are also acti-
vated in response to proinﬂammatory cytokines and which
ultimately suppress the insulin signaling pathway. Therefore
innate immunity, in addition to its immediate response to
pathogens, may also be involved in whole-body and organ-
speciﬁc insulin sensitivity as well as in the regulation of the
energy balance. Interestingly TLRs, notably TLR4, expressed
on both innate and adaptive immune cells, are also found
on cells of insulin-responsive tissue such as adipocytes. TLRs
maythereforerepresentapotentialmoleculargatelinkingin-
ﬂammation with insulin resistance, diabetes, and obesity.
The second aspect developed in this review concerns
the critical importance of the gut microbiota in the devel-
opment of metabolic diseases, particularly obesity. As de-
scribed, this hypothesis started with the fascinating obser-
vation that young adult germ-free mice had only half of
the body fat of their conventional counterparts receiving the
same diet. We attempted to compile the numerous beneﬁts
that arise from a healthy intestinal microbiota (extraction of
nutriments from food; participation in the development and
maturation of the gut immune system, and regulation of fat
storage within adipocytes) and discussed the potential role
of a disturbed ﬂora in metabolic disorders such as obesity.
Again, TLRs appeared to be the link between nutrition, mi-
crobiota, and inﬂammation.
Finally, we showed that immune cells, both from the in-
nate and adaptive immune systems, express TLRs and that
immune responses depend on a critical increase in energy
requirements, preferably met by glucose. Such observations
allow to deduce a quasi parallel between lymphocyte glucose
metabolism and bodily metabolism mostly via the insulin
signaling pathway, and reinforce the link between nutrition,
immune system, energy metabolism, and gut microbiota, re-
sumed in Figure 1.
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